Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 5
1948 4
1949 3
1950 4
1951 6
1952 5
1953 3
1954 4
1956 1
1957 2
1958 1
1959 3
1961 2
1962 3
1963 3
1964 1
1967 1
1970 2
1974 5
1975 60
1976 94
1977 116
1978 110
1979 129
1980 91
1981 118
1982 110
1983 134
1984 157
1985 126
1986 147
1987 141
1988 143
1989 174
1990 182
1991 169
1992 239
1993 203
1994 226
1995 255
1996 216
1997 217
1998 224
1999 198
2000 223
2001 244
2002 277
2003 300
2004 260
2005 309
2006 299
2007 269
2008 218
2009 215
2010 234
2011 223
2012 292
2013 349
2014 364
2015 393
2016 410
2017 379
2018 308
2019 157
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

9,089 results
Results by year
Filters applied: . Clear all
Page 1
Drug-eluting implants for the suppression of metastatic bone disease: current insights.
Pountos I and Giannoudis PV. Expert Rev Med Devices 2018 - Review. PMID 29561689
The progression of the metastatic bone disease can cause significant pain and disability but also could result in the loosening and subsequent failure of the implants. ...This is an inexpensive and safe method that can improve implant stability, prevent local cancer progression and failure of reconstructive devices. ...
The progression of the metastatic bone disease can cause significant pain and disability but also could result in the loosening and subseque …
Engineered titanium implants for localized drug delivery: recent advances and perspectives of Titania nanotubes arrays.
Maher S, et al. Expert Opin Drug Deliv 2018 - Review. PMID 30259776
AREAS COVERED: This review presents an overview of recent development of Ti drug-releasing implants, with emphasis on nanoengineered Titania nanotubes (TNTs) structures, for solving key problems to improve implants osseointegration, overcome inflammation and infection together with providing localized drug delivery (LDD) for bone diseases including cancer. ...To this end, TNTs-Ti implants represent a potential promise for the development of new generation of multifunctional implants with drug release functions. ...
AREAS COVERED: This review presents an overview of recent development of Ti drug-releasing implants, with emphasis on nanoengi …
Progestins and acne vulgaris: a review
Bosanac SS, et al. Dermatol Online J 2018 - Review. PMID 30142728 Free article.
This review will evaluate the association between progestins found in hormonal long-acting reversible contraceptives (intrauterine devices and subdermal implants) and acne, as well as the role of oral contraceptives in acne management. ...
This review will evaluate the association between progestins found in hormonal long-acting reversible contraceptives (intrauterine devices a …
The paradigm shift for drug delivery systems for oral and maxillofacial implants.
Pokrowiecki R. Drug Deliv 2018 - Review. PMID 29968496 Free PMC article.
Targeted, antibacterial drug delivery is most likely desirable in the case of intraosseous implants. Interfering factors such as the oral cavity environment, saliva, the bacterial microbiome, as well as, the characteristics of the alveolar mucosa and peri-implant space must be taken into account when calculating the local pharmacokinetics for antibacterial coatings. ...These parameters may differ between the implant type and its anatomical site. Also, the functional drug concentration in the peri-implant space should be calculated as the amount of the drug released from the implant surface including the concentration of the drug inactivated by biological fluids of the peri-implant space or saliva flow throughout the effective release time....
Targeted, antibacterial drug delivery is most likely desirable in the case of intraosseous implants. Interfering factors such …
A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
He Y, et al. BMC Ophthalmol 2018 - Review. PMID 29784048 Free PMC article.
METHODS: The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databases were comprehensively searched for studies comparing DEX implant with anti-VEGF in patients with DME. ...However, use of the DEX implant has higher risk of intraocular pressure elevation and cataract than anti-VEGF treatment. CONCLUSIONS: Compared with anti-VEGF, DEX implant improved anatomical outcomes significantly. ...
METHODS: The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databases were comprehensively searched for studies comparing D …
Polymer degradation induced drug precipitation in PLGA implants - Why less is sometimes more.
Zlomke C, et al. Eur J Pharm Biopharm 2019. PMID 30902733
Therefore, nifedipine and nicardipine loaded PLGA implants with different drug loads were manufactured by extrusion and investigated. ...With 5% loaded implants a higher drug release compared to 10% drug loaded polymers could be achieved and not only the relative amount of drug release (% of loaded drug), but surprisingly also the absolute amount of the released drug increased. ...
Therefore, nifedipine and nicardipine loaded PLGA implants with different drug loads were manufactured by extrusion and invest …
Synthesis and Characterisation of Photocrosslinked poly(ethylene glycol) diacrylate Implants for Sustained Ocular Drug Delivery.
McAvoy K, et al. Pharm Res 2018. PMID 29368249 Free PMC article.
PURPOSE: To investigate the sustained ocular delivery of small and large drug molecules from photocrosslinked poly(ethylene glycol) diacrylate (PEGDA) implants with varying pore forming agents. ...CONCLUSION: Photocrosslinked PEGDA implant based systems are capable of controlled drug release of both small and large drug molecules through adaptations in the polymer system network. ...
PURPOSE: To investigate the sustained ocular delivery of small and large drug molecules from photocrosslinked poly(ethylene glycol) d …
RETINA
[No authors listed] Retina 2018 - Review. PMID 29889714
Glaucoma Drugs in the Pipeline
Kaufman PL, et al. Asia Pac J Ophthalmol (Phila) 2018 - Review. PMID 30221499
Several new topical drop compounds directly targeting the trabecular meshwork (TM)/Schlemm canal/conventional outflow pathway to reduce outflow resistance have obtained US Food and Drug Administration approval in the past year. ...Alternative therapies that offer long-term IOP lowering while removing the patient from the drug delivery system are moving forward in development. ...
Several new topical drop compounds directly targeting the trabecular meshwork (TM)/Schlemm canal/conventional outflow pathway to reduce outf …
9,089 results
Jump to page
Feedback